EUVIMEDEUVIMED entdecken
Open Access

Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors

Caitlyn L Miller iD, Idit Sagiv-Barfi iD, Patrick Neuhöfer iD, Debra K Czerwinski, Carolyn R Bertozzi, Jennifer R Cochran, Ronald Levy iD

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2200950 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Caitlyn L Miller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Mammary Neoplasms, Animal, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Howard Hughes Medical Institute, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spontaneous tumors that arise in genetically engineered mice recapitulate the natural tumor microenvironment and tumor-immune coevolution observed in human cancers, providing a more physiologically relevant preclinical model relative to implanted tumors. Similar to many cancer patients, oncogene-driven spontaneous tumors are often resistant to immunotherapy, and thus novel agents that can effectively promote antitumor immunity against these aggressive cancers show considerable promise for clinical translation, and their mechanistic assessment can broaden our understanding of tumor immunology. In this study, we performed extensive immune profiling experiments to investigate how tumor-targeted TLR9 stimulation remodels the microenvironment of spontaneously arising tumors during an effective antitumor immune response. To model the clinical scenario of multiple tumor sites, we used MMTV-PyMT transgenic mice, which spontaneously develop heterogeneous breast tumors throughout their 10 mammary glands. We found that i.v. administration of a tumor-targeting TLR9 agonist, referred to as PIP-CpG, induced a systemic T cell–mediated immune response that not only promoted regression of existing mammary tumors, but also elicited immune memory capable of delaying growth of independent newly arising tumors. Within the tumor microenvironment, PIP-CpG therapy initiated an inflammatory cascade that dramatically amplified chemokine and cytokine production, prompted robust infiltration and expansion of innate and adaptive immune cells, and led to diverse and unexpected changes in immune phenotypes. This study demonstrates that effective systemic treatment of an autochthonous multisite tumor model can be achieved using a tumor-targeted immunostimulant and provides immunological insights that will inform future therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mammary Neoplasms, AnimalBreast NeoplasmsMiceAnimalsHumansFemaleToll-Like Receptor 9Mice, TransgenicAdjuvants, ImmunologicTumor MicroenvironmentCell Line, Tumor

Substanzen

Toll-Like Receptor 9Adjuvants, ImmunologicTLR9 protein, human

Autor:innen und Institutionen

  • Department of Bioengineering, Stanford University, Stanford, CA.
  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.
  • Department of Medicine, Stanford University, Stanford, CA.
  • Department of Biochemistry, Stanford University, Stanford, CA.
  • Stanford Cancer Institute, Stanford University, Stanford, CA.
  • Department of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA.

ORCID-Profile: Caitlyn L Miller, Idit Sagiv-Barfi, Patrick Neuhöfer, Ronald Levy

Förderung

  • NCI NIH HHS
  • Howard Hughes Medical Institute
  • HHS | National Institutes of Health
  • St Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant
  • National Science Foundation
  • American Society of Hematology
  • American Cancer Society

Zitieren

APA

Miller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Bertozzi, C. R., Cochran, J. R., & Levy, R. (2023). Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200950

Vancouver

Miller CL, Sagiv-Barfi I, Neuhöfer P, Czerwinski DK, Bertozzi CR, Cochran JR, et al. Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200950

BibTeX
@article{Miller2023,
  author = {Miller, Caitlyn L and Sagiv-Barfi, Idit and Neuhöfer, Patrick and Czerwinski, Debra K and Bertozzi, Carolyn R and Cochran, Jennifer R and Levy, Ronald},
  title = {Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2200950}
}
Kostenlos starten →